Fig 1: S100A8 enhances tumor-induced migration of vascular endothelial cells in vitro. HUVEC migration was assessed by Transwell migration assays in response to (A) RBE and (B) HCCC-9810 cholangiocarcinoma cell lines after overexpression or knockdown of S100A8, respectively. *P<0.05 with comparisons indicated by brackets. S100A8, S100 calcium-binding protein A8; HUVEC, human umbilical vein endothelial cell; OE, overexpression; KD, knockdown; NC, negative control.
Fig 2: Effects of E2 and EAIs on S100A8 expression in SOECs.(A) The relative mRNA expression levels of S100A8 after different times (5, 6, 7, and 8 h) and different concentrations (10−6, 10−7, 10−8, and 10−9 M) of E2 treatment. The data represent the mean ± standard error (SEM) of three replicate experiments (n = 3). All values are normalized to β-actin expression. (B) Immunofluorescent detection of S100A8 before (control) or after treatment with E2 (10−8 M) for 7 h. The target proteins are indicated with green fluorescence, and nuclei are indicated with blue fluorescence. The scale bars represent 100 μm or 50 μm. (C) Effects of three EAIs (G-15: 10−7 M, fulvestrant: 10−9 M, tamoxifen: 10−7 M) or combinations thereof on E2-dependent S100A8 upregulation in SOECs. S100A8 expression was tested in different groups by q-PCR and WB. The data represent the mean ± SEM of three replicate experiments. The values shown are normalized to GAPDH expression. * (p < 0.05) and ** (p < 0.01) represent significant difference compared with the control group.
Fig 3: Regulation of S100A8 and S100A9 mRNA expression by BET-bromodomain inhibition. qRT-PCR was used to show that regulation of S100A8 and S100A9 mRNA by JQ1 in AML cell lines (a) and primary mononuclear cells (b). OCI-AML3 cells were used to show the effect of JQ1 was (c) dose-dependent, (d) time-dependent, and (e) reversible. 0.5μM JQ1 was used for time course and reversibility experiments. Results are expressed relative to GAPDH (mean ± SEM, n=3).
Fig 4: The control and the S100A8-knockout plasmid vectors.
Fig 5: Expression change trends of five genes (S100A8, S100A9, S100A12, CXCR4, and CYP1B1) in SOECs following different treatment times with E2.(A) Expression change trends of genes with increasing E2-treatment times (0, 1.5, 3.5, and 5.5 h), as detected by RNA-seq. (B) Expression change trends of genes with increasing E2-treatment times (0, 2, 4, and 6 h), as verified by q-PCR. * (p < 0.05) and ** (p < 0.01) represent significant difference compared with the control group.
Supplier Page from Abcam for Anti-MRP8 antibody